• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

1DROP Raises $4.25M to Support Commercialization of Portable Medical Diagnostics Platform

by Jasmine Pennic 10/31/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

1DROP Raises $4.25M to Support Commercialization of Portable Medical Diagnostics Platform

1DROP, a life sciences startup developing and commercializing an easy to use laboratory quality, portable medical diagnostic testing platform has raised $4.25 million in Series A funding led by led by Christian Wildmoser (former partner CVC Capital Partners & Swiss Startup Group Investor). The round also included participation from private investors of the Swiss Startup Group including Dr. Hans-Peter Strebel (owner of On Your Marks), Beat Schillig (IFJ Institute for Young Entrepreneurs) and Jean-Philippe de Toledo(CEO of Pharmacie Principale).

How It Works

One drop of blood contains a massive amount of information, millions of cells, trillions of small molecules like proteins, nucleic acids and ions. 1Drop provides personalized health insights by easily measuring biomarkers from a tiny drop of blood immediately in front of the patient to produce diagnostic test results within 15 minutes. Through the integration of biochemical reagents directly on the microfluidic chips, 1DROP dramatically miniaturize biochemical reactions preserving valuable samples and reagents, increasing the sensitivity of tests, accelerating mass transport limited reactions, leading to a faster time to high-quality results.

1DROP’s innovative diagnostic solutions for multiplexed assays of proteins, nucleic acids and peptides serve as tools for the development of new therapies, disease research, and clinical diagnostic tests.

Recent Traction

1DROP is currently working with three pharmaceutical partners to create companion diagnostic products for cardiology, autoimmune disease, and glucose metabolism drug candidates. 1DROP’s business model is to actively work with pharmaceutical, diagnostic and biomarker companies to develop more integrated solutions between diagnostics and therapeutics that improve the outcome for the individual patient.

1DROP Commercialization Plans

1DROP plans to use the Series A funding to expand research and development and to commercialize the portable medical diagnostics platform. In addition, the company plans to perform clinical studies to demonstrate the device’s suitability for near-patient use and to develop additional panels of tests.

1DROP plans to obtain the appropriate regulatory approvals and integrate diagnostic test results with electronic medical records (EMRs). Through the use of machine learning, 1DROP  will establish patterns of disease evolution and clinical outcomes.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: 1DROP, Biomarkers, Clinical Diagnostics, diagnostic testing, Digital Biomarkers, Digital Therapeutics, Life Sciences

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |